Abemaciclib metabolite M18 (hydrochloride)
CAT:
804-HY-126534A-03
Size:
25 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Abemaciclib metabolite M18 (hydrochloride)
- Product Name Alternative: LSN3106729 (hydrochloride)
- CAS Number: 2704316-82-3
- UNSPSC Description: Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].
- Target Antigen: CDK; Ligands for Target Protein for PROTAC
- Type: Reference compound
- Related Pathways: Cell Cycle/DNA Damage;PROTAC
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/abemaciclib-metabolite-m18-hydrochloride.html
- Purity: 98.01
- Solubility: DMSO : 125 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
- Smiles: FC(C=N1)=C(C2=CC(N(C(C)C)C(CO)=N3)=C3C(F)=C2)N=C1NC4=NC=C(C=C4)CN5CCNCC5.[H]Cl
- Molecular Weight: 531.00
- References & Citations: [1]Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1.|[2]Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study.|[3]Palaniappan, et al. Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res. 2016-7-15; 76 (14_Supplement): CT153. |[4]Goel S, et al. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018 Nov;28(11):911-925.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: No Development Reported